enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. 5 cancer types where screenings save the most lives - AOL

   www.aol.com/5-cancer-types-where-screenings...

   Prevention and screening beat out treatment advances in terms of preventing deaths for cervical, colorectal, lung and prostate cancers. Breast cancer was the only type for which treatment advances ...

3. What to Know About Complementary Therapies for Prostate Cancer

   www.aol.com/know-complementary-therapies...

   “Two servings of fish per week after diagnosis was associated with a 17% lower risk of prostate cancer recurrence,” wrote the Prostate 8 team, citing a study in the journal Cancer Causes and ...

4. STAMPEDE (clinical trial) - Wikipedia

   en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

   Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.

5. EPI-001 - Wikipedia

   en.wikipedia.org/wiki/EPI-001

   EPI-001 inhibits AR-dependent proliferation of human prostate cancer cells while having no significant effects on cells that do not require the AR for growth and survival. [2] EPI-001 has specificity to the AR (aside from the PPARγ) and has excellent anti-tumor activity in vivo with xenografts of CRPC.

6. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Prostate cancer is the second-most frequently diagnosed cancer in men, and the second-most frequent cause of cancer death in men (after lung cancer). [2] [3] Around 1.2 million new cases of prostate cancer are diagnosed each year, and over 350,000 people die of the disease, annually. [2]

7. Prostvac - Wikipedia

   en.wikipedia.org/wiki/Prostvac

   PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]